The treatment of alcoholism in France

Drug and Alcohol Dependence

Volumn 39, Issue SUPPL. 1, 1995, Pages

  Batel, Philippe ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Acamprosate; Alcoholism; Dopaminergic agents; Lithium; Naltrexone; Pharmacotherapy; Psychotherapy

Indexed keywords

ACAMPROSATE; APOMORPHINE; BROMOCRIPTINE; BUSPIRONE; CITALOPRAM; FLUOXETINE; LEVODOPA; LITHIUM; MELPERONE; MEPROBAMATE; NALTREXONE; NIALAMIDE; PHENYTOIN; TETRABAMATE; VILOXAZINE; ZIMELDINE;

ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; FOLLOW UP; FRANCE; GUILLAIN BARRE SYNDROME; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; PUBLIC HEALTH; SIDE EFFECT;

ALCOHOL DETERRENTS; ALCOHOLISM; FOLLOW-UP STUDIES; FRANCE; HUMAN; META-ANALYSIS; NARCOTIC ANTAGONISTS; PSYCHOTROPIC DRUGS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0029116841     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/0376-8716(95)01169-Y     Document Type: Article

References (42)

1. Alcoholism and depression: a placebo controlled study with viloxazine
2. Le syndrome subaigu de sevrage et son traitement chez le malade alcoolique
3. Traitement de la maladie alcoolique, Encycl Méd Chir, (Paris, France)
4. Bromocriptine in the prevention of alcohol abuse
5. Buspirone in the treatment of alcoholic patients
6. A double blind study with melperone and placebo in the treatment of chronic alcoholics
7. A double-blind study of melperone and placebo in hospitalized chronic alcoholics in postintoxication phase
8. Meta-analysis in clinical trials
9. Bromocriptine in the treatment of alcohol dependence
10. When drug regulation fails
11. Ginillain-Barre's syndrome following zimeldine treatment
12. A double-blind, placebo-controlled trial of lithium carbonate therapy for alcoholism
13. Gamma-hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study
14. Pharmacologic maintenance of abstinence in patients with alcoholism: no efficacy of 5-hydroxytryptophan or levodopa
15. Effects of fluoxetine and Ca-acetyl-homotaurinate on alcohol intake in familial and nonfamilial alcoholic patients
16. Inhibition of catecholamine biosynthesis by apomorphine
17. Prévalence du risque et des maladies liés à l'alcool dans la clientèle adulte du généraliste
18. Phenytoin, metronidazole and multivitamins in the treatment of alcoholism
19. A trial of fenfluramine in the treatment of the chronic alcoholic patient
20. Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele
21. Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics
22. Acamprosate appears to decrease alcohol intake in weaned alcoholics
23. Zimelidine-induced variations in alcohol intake by non-depressed heavy drinkers
24. Moderation of ethanol drinking: role of enhanced serotonergic neurotransmission
25. The serotonin uptake inhibitor citalopram attenuates ethanol intake
26. Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers
27. Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers
28. Naltrexone and coping skills therapy for alcohol dependence: a controlled study
29. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol
30. Prevalence des maladies alcooliques dans un hôpital universitaire de la banlieue parisienne
31. Tests of opioid deficiency hypotheses: of alcoholism
32. Replication of a study of nialamide in the treatment of convalescing alcoholics with emphasis on prediction of response
33. Gamma-hydroxybutyrate a possible neurotransmitter
34. Naltrexone blocks the post-shock increase of ethanol consumption
35. Naltrexone and the treatment of alcohol-dependence: initial observations
36. Naltrexone in the treatment of alcohol dependence
37. Effects of apomorphine and apomorphine-l-dopa-carbidopa on alcohol post-intoxication symptoms
38. Beta blockade during and after myocardial infarction: an overview of the randomized trials